Steve E. Krognes is CFO & Treasurer at Denali Therapeutics Inc. (DNLI). They have made 20 open-market trades across 2 companies since 2020, most recently 2026-09-16.
CIK 0001666236
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 20 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GH | 7,906 | $1.3M |
| DNLI | 38,202 | $673K |
| Total | $1.9M |
Shares reported on the most recent Form 4, priced at the 2026-09-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GH | SELL | 2026-09-16 | 2026-09-17 | $175.74 | $1.2M | -2.6% | — | — |
| GH | SELL | 2026-06-04 | 2026-06-05 | $132.51 | $1.2M | +0.3% | +31.1% | +25.0% |
| DNLI | SELL | 2025-01-07 | 2025-01-08 | $20.81 | $139K | +13.9% | +8.7% | -43.9% |
| DNLI | SELL · 10b5-1 | 2024-12-31 | 2025-01-03 | $20.25 | $608K | +2.7% | +3.5% | -39.4% |
| DNLI | SELL · 10b5-1 | 2024-09-30 | 2024-10-02 | $29.03 | $871K | -6.5% | -5.7% | -29.0% |
| DNLI | SELL | 2024-08-20 | 2024-08-22 | $23.79 | $41K | +4.4% | +25.4% | +1.3% |
| DNLI | SELL · 10b5-1 | 2024-06-13 | 2024-07-03 | $22.11 | $679K | +13.7% | +3.8% | +36.1% |
| DNLI | SELL · 10b5-1 | 2024-04-01 | 2024-04-02 | $20.50 | $1.9M | -4.1% | -11.7% | +15.6% |
| DNLI | SELL | 2024-02-13 | 2024-02-15 | $17.29 | $48K | +13.7% | +13.0% | +17.3% |
| DNLI | SELL | 2024-01-05 | 2024-01-09 | $19.43 | $125K | -11.2% | -11.8% | -2.4% |
| DNLI | SELL | 2023-08-21 | 2023-08-23 | $22.60 | $32K | +4.5% | -2.9% | -20.2% |
| DNLI | SELL | 2023-02-13 | 2023-02-15 | $30.10 | $128K | -8.7% | -21.6% | -1.5% |
| DNLI | SELL | 2023-02-08 | 2023-02-10 | $30.88 | $43K | -8.1% | -19.5% | -4.9% |
| DNLI | SELL | 2023-01-05 | 2023-01-09 | $28.44 | $169K | +5.6% | +10.7% | -12.6% |
| DNLI | SELL | 2022-08-19 | 2022-08-23 | $33.22 | $150K | -13.4% | -15.2% | -8.6% |
| DNLI | SELL | 2022-02-11 | 2022-02-15 | $34.69 | $178K | -7.6% | -7.3% | -34.0% |
| DNLI | SELL | 2022-02-09 | 2022-02-11 | $37.09 | $48K | -5.5% | -16.8% | -37.4% |
| DNLI | SELL | 2022-01-05 | 2022-01-07 | $44.75 | $199K | -19.3% | -11.8% | -20.9% |
| DNLI | SELL | 2021-08-19 | 2021-08-23 | $49.55 | $217K | +8.4% | +0.7% | -12.4% |
| DNLI | SELL | 2021-03-15 | 2021-03-16 | $61.89 | $6.2M | -10.4% | -9.1% | +21.8% |
| DNLI | SELL | 2021-02-16 | 2021-02-18 | $65.09 | $6.5M | -1.1% | -3.3% | -12.8% |
| DNLI | SELL | 2021-02-11 | 2021-02-16 | $70.26 | $398K | +13.4% | -6.0% | -15.3% |
| DNLI | SELL | 2021-01-15 | 2021-01-20 | $71.45 | $7.1M | -10.2% | -15.9% | -32.6% |
| DNLI | SELL | 2020-03-30 | 2020-04-01 | $19.48 | $28K | +29.2% | +37.7% | +52.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.